US2021369841A1PendingUtilityA1

Anti-rspo3 antibodies and methods of use

63
Assignee: GENENTECH INCPriority: Apr 14, 2016Filed: Dec 16, 2020Published: Dec 2, 2021
Est. expiryApr 14, 2036(~9.7 yrs left)· nominal 20-yr term from priority
Inventors:Elaine Storm
C07K 16/2863C07K 16/30C07K 2317/90C07K 2317/94C07K 2317/41C07K 2317/526C07K 2317/524C07K 2317/71C07K 2317/24C07K 2317/92C07K 2317/76C07K 16/3046C07K 2317/33C07K 2317/20A61K 45/06A61K 2039/505C07K 16/18A61K 39/3955C07K 16/2803
63
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Provided herein are anti-RSPO3 antibodies and methods of using the same.

Claims

exact text as granted — not AI-modified
1 . An isolated antibody that binds to human R-spondin 3 (RSPO3), wherein the antibody comprises:
 (a) a light chain variable region (VL) comprising (i) a first light chain hypervariable region (HVR-L1) comprising the amino acid sequence of SEQ ID NO:5, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:6, and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:7; and a heavy chain variable region (VH) comprising (i) a first heavy chain hypervariable region (HVR-H1) comprising the amino acid sequence of SEQ ID NO:8, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:9, and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO:10;   (b) a VL comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:11, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:12, and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:13; and a VH comprising (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:14, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:15, and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO:16; or   (c) a VL comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:17, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:18, and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:19; and a VH comprising (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:20, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:21, and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO:22.   
     
     
         2 .- 49 . (canceled)

Join the waitlist — get patent alerts

Track US2021369841A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.